Aegis Affirms Progenics Pharma (PGNX) at 'Buy'; Solid Relistor Results Fuel Q3 Revenue Gains (VRX)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Aegis Capital affirms Progenics Pharma (Nasdaq: PGNX) at Buy with a price target of $11 following Q3 results issued on Monday
3Q revenues were driven by the approval (which triggered a $50 million milestone by Valeant Pharmaceuticals) and US launch of oral Relistor for OIC in adults with chronic non-cancer pain in July and September, respectively. Progenics received $3.3 million in Relistor royalties from $22.1 million in Valeant sales of Relistor (oral and SUBQ). Progenics also announced a Relistor royalty-based loan that has brought PGNX cash to $98.9 million, which we expect will allow PGNX to fund Azedra to initial commercialization and develop its prostate assets through 2018. PGNX continues to expect Azedra top-line data in 1H17, and we view the trial as substantially de-risked and expect a late 2017 approval due to Breakthrough Designation status, which would make Azedra the first approved treatment for malignant or recurrent pheochromocytoma and paraganglioma in the US – we believe Azedra represents about a $150 million market opportunity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Francesca's (FRAN) Following 3Q Report
- Guggenheim Cuts Price Target on Michaels Cos. (MIK) to $30; Reiterates Buy
- Wedbush Upgrades Discover Financial (DFS) to Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!